

| Audit Review Table | | | | |
|--|------------------------|-------------|--------------------------|----------------|
| Molina Healthcare of New Mexico (Org ID: 955, SubID: 4112, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None) | | | | |
| Measurement Year - 2016; Date & Timestamp - 6/22/2017 5:42:40 PM | | | | |
| The Auditor lock has been applied to this submission. | | | | |
| Measure/Data Element | Benefit Offered | Rate | Audit Designation | Comment |
| Effectiveness of Care: Prevention and | | | | |
| Adult BMI Assessment (aba) | | 79.34% | R | Reportable |
| Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc) | | | | |
| <i>BMI Percentile</i> | | 62.25% | R | Reportable |
| <i>Counseling for Nutrition</i> | | 55.41% | R | Reportable |
| <i>Counseling for Physical Activity</i> | | 51.66% | R | Reportable |
| Childhood Immunization Status (cis) | | | | |
| <i>DTaP</i> | | 76.38% | R | Reportable |
| <i>IPV</i> | | 88.08% | R | Reportable |
| <i>MMR</i> | | 88.30% | R | Reportable |
| <i>HiB</i> | | 87.20% | R | Reportable |
| <i>Hepatitis B</i> | | 87.64% | R | Reportable |
| <i>VZV</i> | | 88.08% | R | Reportable |
| <i>Pneumococcal Conjugate</i> | | 76.38% | R | Reportable |
| <i>Hepatitis A</i> | | 84.99% | R | Reportable |
| <i>Rotavirus</i> | | 71.30% | R | Reportable |
| <i>Influenza</i> | | 44.81% | R | Reportable |
| <i>Combination #2</i> | | 73.07% | R | Reportable |
| <i>Combination #3</i> | | 69.76% | R | Reportable |
| <i>Combination #4</i> | | 67.99% | R | Reportable |
| <i>Combination #5</i> | | 59.60% | R | Reportable |
| <i>Combination #6</i> | | 39.07% | R | Reportable |
| <i>Combination #7</i> | | 58.06% | R | Reportable |
| <i>Combination #8</i> | | 39.07% | R | Reportable |
| <i>Combination #9</i> | | 35.32% | R | Reportable |
| <i>Combination #10</i> | | 35.32% | R | Reportable |
| Immunizations for Adolescents (ima) | | | | |
| <i>Meningococcal</i> | | 77.70% | R | Reportable |

| | | | | |
|--|---|--------|---|------------|
| <i>Tdap</i> | | 90.07% | R | Reportable |
| <i>HPV</i> | | 25.39% | R | Reportable |
| <i>Combination #1</i> | | 76.38% | R | Reportable |
| <i>Combination #2</i> | | 24.50% | R | Reportable |
| Lead Screening in Children (lsc) | | 37.97% | R | Reportable |
| Breast Cancer Screening (bcs) | | 56.58% | R | Reportable |
| Cervical Cancer Screening (ccs) | | 58.71% | R | Reportable |
| Chlamydia Screening in Women (chl) | | | | |
| <i>16-20 Years</i> | | 45.21% | R | Reportable |
| <i>21-24 Years</i> | | 56.45% | R | Reportable |
| <i>Total</i> | | 50.20% | R | Reportable |
| Effectiveness of Care: Respiratory | | | | |
| Appropriate Testing for Children with Pharyngitis (cwp) | Y | 62.22% | R | Reportable |
| Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr) | | 31.69% | R | Reportable |
| Pharmacotherapy Management of COPD Exacerbation (pce) | Y | | | |
| <i>Systemic Corticosteroid</i> | | 65.18% | R | Reportable |
| <i>Bronchodilator</i> | | 81.41% | R | Reportable |
| Medication Management for People With Asthma (mma) | Y | | | |
| <i>5-11 Years: Medication Compliance 50%</i> | | 46.50% | R | Reportable |
| <i>5-11 Years: Medication Compliance 75%</i> | | 21.96% | R | Reportable |
| <i>12-18 Years: Medication Compliance 50%</i> | | 44.41% | R | Reportable |
| <i>12-18 Years: Medication Compliance 75%</i> | | 20.70% | R | Reportable |
| <i>19-50 Years: Medication Compliance 50%</i> | | 54.49% | R | Reportable |
| <i>19-50 Years: Medication Compliance 75%</i> | | 30.73% | R | Reportable |
| <i>51-64 Years: Medication Compliance 50%</i> | | 72.80% | R | Reportable |
| <i>51-64 Years: Medication Compliance 75%</i> | | 49.79% | R | Reportable |
| <i>Total: Medication Compliance 50%</i> | | 50.78% | R | Reportable |
| <i>Total: Medication Compliance 75%</i> | | 26.83% | R | Reportable |
| Asthma Medication Ratio (amr) | Y | | | |
| <i>5-11 Years</i> | | 72.47% | R | Reportable |
| <i>12-18 Years</i> | | 57.84% | R | Reportable |

| | | | | |
|--|---|--------|----|--------------|
| 19-50 Years | | 47.18% | R | Reportable |
| 51-64 Years | | 57.68% | R | Reportable |
| Total | | 59.58% | R | Reportable |
| Effectiveness of Care: Cardiovascular | | | | |
| Controlling High Blood Pressure (cbp) | | 57.75% | R | Reportable |
| Persistence of Beta-Blocker Treatment After a Heart Attack (pbh) | Y | 71.59% | R | Reportable |
| Statin Therapy for Patients With Cardiovascular Disease (spc) | Y | | | |
| Received Statin Therapy: 21-75 Years (Male) | | 74.32% | R | Reportable |
| Statin Adherence 80%: 21-75 Years (Male) | | 56.68% | R | Reportable |
| Received Statin Therapy: 40-75 Years (Female) | | 73.93% | R | Reportable |
| Statin Adherence 80%: 40-75 Years (Female) | | 57.05% | R | Reportable |
| Received Statin Therapy: Total | | 74.16% | R | Reportable |
| Statin Adherence 80%: Total | | 56.84% | R | Reportable |
| Effectiveness of Care: Diabetes | | | | |
| Comprehensive Diabetes Care (cdc) | | | | |
| Hemoglobin A1c (HbA1c) Testing | | 87.20% | R | Reportable |
| HbA1c Poor Control (>9.0%) | | 41.06% | R | Reportable |
| HbA1c Control (<8.0%) | | 44.37% | R | Reportable |
| HbA1c Control (<7.0%) | | | NR | Not Reported |
| Eye Exam (Retinal) Performed | | 59.82% | R | Reportable |
| Medical Attention for Nephropathy | | 88.96% | R | Reportable |
| Blood Pressure Control (<140/90 mm Hg) | | 63.13% | R | Reportable |
| Statin Therapy for Patients With Diabetes (spd) | Y | | | |
| Received Statin Therapy | | 54.35% | R | Reportable |
| Statin Adherence 80% | | 52.63% | R | Reportable |
| Effectiveness of Care: Musculoskeletal | | | | |
| Disease-Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art) | Y | 78.16% | R | Reportable |
| Effectiveness of Care: Behavioral | | | | |
| Antidepressant Medication Management (amm) | Y | | | |
| Effective Acute Phase Treatment | | 47.19% | R | Reportable |
| Effective Continuation Phase Treatment | | 32.11% | R | Reportable |
| Follow-Up Care for Children Prescribed ADHD Medication (add) | Y | | | |

| | | | | |
|--|---|--------|----|-------------------|
| <i>Initiation Phase</i> | | 59.71% | R | Reportable |
| <i>Continuation and Maintenance (C&M) Phase</i> | | 69.42% | R | Reportable |
| Follow-Up After Hospitalization for Mental Illness (fuh) | Y | | | |
| <i>30-Day Follow-Up</i> | | 63.81% | R | Reportable |
| <i>7-Day Follow-Up</i> | | 37.50% | R | Reportable |
| Follow-Up After Emergency Department Visit for Mental Illness (fum) | Y | | | |
| <i>30-Day Follow-Up</i> | | 57.97% | R | Reportable |
| <i>7-Day Follow-Up</i> | | 42.26% | R | Reportable |
| Follow-Up After Emergency Department Visit for Alcohol and Other Drug Dependence (fua) | Y | | | |
| <i>30-Day Follow-Up: 13-17 Years</i> | | 8.27% | R | Reportable |
| <i>7-Day Follow-Up: 13-17 Years</i> | | 6.02% | R | Reportable |
| <i>30-Day Follow-Up: 18+ Years</i> | | 16.36% | R | Reportable |
| <i>7-Day Follow-Up: 18+ Years</i> | | 9.39% | R | Reportable |
| <i>30-Day Follow-Up: Total</i> | | 15.95% | R | Reportable |
| <i>7-Day Follow-Up: Total</i> | | 9.22% | R | Reportable |
| Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd) | Y | 77.27% | R | Reportable |
| Diabetes Monitoring for People With Diabetes and Schizophrenia (smd) | | 63.69% | R | Reportable |
| Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc) | | 57.89% | NA | Small Denominator |
| Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa) | Y | 54.65% | R | Reportable |
| Metabolic Monitoring for Children and Adolescents on Antipsychotics (apm) | Y | | | |
| <i>1-5 Years</i> | | 6.67% | NA | Small Denominator |
| <i>6-11 Years</i> | | 26.14% | R | Reportable |
| <i>12-17 Years</i> | | 29.33% | R | Reportable |

| | | | | |
|--|---|--------|----|-------------------|
| <i>Total</i> | | 27.82% | R | Reportable |
| Effectiveness of Care: Medication | | | | |
| Annual Monitoring for Patients on Persistent Medications (mpm) | Y | | | |
| <i>ACE Inhibitors or ARBs</i> | | 83.29% | R | Reportable |
| <i>Digoxin</i> | | 44.83% | NA | Small Denominator |
| <i>Diuretics</i> | | 84.11% | R | Reportable |
| <i>Total</i> | | 83.48% | R | Reportable |
| Effectiveness of Care: | | | | |
| Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs) | | 1.90% | R | Reportable |
| Appropriate Treatment for Children With URI (uri) | Y | 87.30% | R | Reportable |
| Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab) | Y | 24.64% | R | Reportable |
| Use of Imaging Studies for Low Back Pain (lbp) | | 69.85% | R | Reportable |
| Use of Multiple Concurrent Antipsychotics in Children and Adolescents (apc) | Y | | | |
| <i>1-5 Years</i> | | 0.00% | NA | Small Denominator |
| <i>6-11 Years</i> | | 1.26% | R | Reportable |
| <i>12-17 Years</i> | | 1.33% | R | Reportable |
| <i>Total</i> | | 1.27% | R | Reportable |
| Access/Availability of Care | | | | |
| Adults' Access to Preventive/Ambulatory Health Services (aap) | | | | |
| <i>20-44 Years</i> | | 71.99% | R | Reportable |
| <i>45-64 Years</i> | | 80.26% | R | Reportable |
| <i>65+ Years</i> | | 41.01% | R | Reportable |
| <i>Total</i> | | 74.35% | R | Reportable |
| Children and Adolescents' Access to Primary Care Practitioners (cap) | | | | |
| <i>12-24 Months</i> | | 95.25% | R | Reportable |
| <i>25 Months - 6 Years</i> | | 86.88% | R | Reportable |
| <i>7-11 Years</i> | | 90.54% | R | Reportable |
| <i>12-19 Years</i> | | 90.52% | R | Reportable |

| | | | | |
|---|---|--------|----|-------------------|
| Annual Dental Visit (adv) | Y | | | |
| 2-3 Years | | 58.15% | R | Reportable |
| 4-6 Years | | 75.04% | R | Reportable |
| 7-10 Years | | 78.42% | R | Reportable |
| 11-14 Years | | 75.57% | R | Reportable |
| 15-18 Years | | 65.92% | R | Reportable |
| 19-20 Years | | 43.82% | R | Reportable |
| Total | | 70.43% | R | Reportable |
| Initiation and Engagement of AOD Dependence Treatment (iet) | Y | | | |
| Initiation of AOD Treatment: 13-17 Years | | 43.47% | R | Reportable |
| Engagement of AOD Treatment: 13-17 Years | | 12.50% | R | Reportable |
| Initiation of AOD Treatment: 18+ Years | | 36.73% | R | Reportable |
| Engagement of AOD Treatment: 18+ Years | | 12.33% | R | Reportable |
| Initiation of AOD Treatment: Total | | 37.16% | R | Reportable |
| Engagement of AOD Treatment: Total | | 12.34% | R | Reportable |
| Prenatal and Postpartum Care (ppc) | | | | |
| Timeliness of Prenatal Care | | 77.40% | R | Reportable |
| Postpartum Care | | 54.81% | R | Reportable |
| Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (app) | Y | | | |
| 1-5 Years | | 50.00% | NA | Small Denominator |
| 6-11 Years | | 57.94% | R | Reportable |
| 12-17 Years | | 66.51% | R | Reportable |
| Total | | 63.44% | R | Reportable |
| Utilization | | | | |
| Frequency of Ongoing Prenatal Care (fpc) | | | | |
| <21 Percent | | 7.38% | R | Reportable |
| 21-40 Percent | | 8.05% | R | Reportable |
| 41-60 Percent | | 10.07% | R | Reportable |
| 61-80 Percent | | 17.00% | R | Reportable |
| 81+ Percent | | 57.49% | R | Reportable |
| Well-Child Visits in the First 15 Months of Life (w15) | | | | |
| 0 Visits | | 1.12% | R | Reportable |
| 1 Visit | | 3.13% | R | Reportable |
| 2 Visits | | 4.02% | R | Reportable |

| | | | | |
|--|---|--------|----|--------------|
| 3 Visits | | 6.47% | R | Reportable |
| 4 Visits | | 9.60% | R | Reportable |
| 5 Visits | | 16.52% | R | Reportable |
| 6+ Visits | | 59.15% | R | Reportable |
| Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34) | | 64.39% | R | Reportable |
| Adolescent Well-Care Visits (awc) | | 47.68% | R | Reportable |
| Frequency of Selected Procedures (fsp) | | | R | Reportable |
| Ambulatory Care: Total (amba) | | | R | Reportable |
| Ambulatory Care: Dual Eligibles (ambb) | | | NR | Not Reported |
| Ambulatory Care: Disabled (ambc) | | | NR | Not Reported |
| Ambulatory Care: Other (ambd) | | | NR | Not Reported |
| Inpatient Utilization--General Hospital/Acute Care: Total (ipua) | | | R | Reportable |
| Inpatient Utilization--General Hospital/Acute Care: Dual Eligibles (ipub) | | | NR | Not Reported |
| Inpatient Utilization--General Hospital/Acute Care: Disabled (ipuc) | | | NR | Not Reported |
| Inpatient Utilization--General Hospital/Acute Care: Other (ipud) | | | NR | Not Reported |
| Identification of Alcohol and Other Drug Services: Total (iada) | Y | | R | Reportable |
| Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb) | N | | NB | No Benefit |
| Identification of Alcohol and Other Drug Services: Disabled (iadc) | N | | NB | No Benefit |
| Identification of Alcohol and Other Drug Services: Other (iadd) | N | | NB | No Benefit |
| Mental Health Utilization: Total (mpta) | Y | | R | Reportable |
| Mental Health Utilization: Dual Eligibles (mptb) | N | | NB | No Benefit |
| Mental Health Utilization: Disabled (mptc) | N | | NB | No Benefit |
| Mental Health Utilization: Other (mptd) | N | | NB | No Benefit |
| Antibiotic Utilization: Total (abxa) | Y | | R | Reportable |
| Antibiotic Utilization: Dual Eligibles (abxb) | N | | NB | No Benefit |
| Antibiotic Utilization: Disabled (abxc) | N | | NB | No Benefit |

| | | | | |
|--|---|--|----|--------------|
| Antibiotic Utilization: Other (abxd) | N | | NB | No Benefit |
| Standardized Healthcare-Associated Infection Ratio (hai) | | | R | Reportable |
| Health Plan Descriptive | | | | |
| Board Certification (bcr) | | | NR | Not Reported |
| Enrollment by Product Line: Total (enpa) | | | R | Reportable |
| Enrollment by Product Line: Dual Eligibles (enpb) | | | NR | Not Reported |
| Enrollment by Product Line: Disabled (enpc) | | | NR | Not Reported |
| Enrollment by Product Line: Other (enpd) | | | NR | Not Reported |
| Enrollment by State (ebs) | | | R | Reportable |
| Language Diversity of Membership (ldm) | | | R | Reportable |
| Race/Ethnicity Diversity of Membership (rdm) | | | R | Reportable |
| Total Membership (tlm) | | | R | Reportable |
| Measures Collected using Electronic | | | | |
| Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (dms) | | | | |
| <i>Inclusion in ECDS: Total</i> | | | NR | Not Reported |
| <i>Utilization of PHQ-9: Total</i> | | | NR | Not Reported |
| Depression and Remission or Response for Adolescents and Adults (drr) | | | | |
| <i>EDCS Coverage: Total</i> | | | NR | Not Reported |
| <i>Follow-up PHQ-9: Total</i> | | | NR | Not Reported |
| <i>Depression Remission: Total</i> | | | NR | Not Reported |
| <i>Depression Response: Total</i> | | | NR | Not Reported |